Disability and Rationing of Care amid COVID-19
By Katrina N. Jirik,
Bill of Health
| 04. 13. 2020
As medical professionals and bioethicists deal with the conundrum involved in establishing rationing of care guidelines, the mantra of the disability community comes to mind. Nothing about us, without us.
As health care resources grow increasingly scarce amid the COVID-19 pandemic, states, hospitals, and individuals are forced to make tough decisions about the rationing of care. These decisions are often framed in terms of medical and/or legal criteria. However, many people, especially the physicians who make the difficult decisions, realize they have a huge moral component related to perceptions of the value of an individual’s life.
Various states have triage guidelines in place, which differ somewhat, but primarily reflect a utilitarian goal of saving the most people with the least expenditure of finite resources. This is where the societal issue of the value of the life of a person with a disability comes into play.
Many of the guidelines state that the decision to treat needs to consider co-morbidities and anticipated resource use in the future. This is updated eugenic thought, whereby you have only the survival of the fittest, with an assumed understanding of what “the fittest” actually entails. These conceptions are based on a medical model of disability, something many people with disabilities find extremely problematic. It’s also...
Related Articles
By Abby McCloskey, The Dallas Morning News | 10.10.2025
We Texans like to do things our way — leave some hide on the fence rather than stay corralled, as goes a line in Wallace O. Chariton’s Texas dictionary This Dog’ll Hunt. Lately, I’ve been wondering what this ethos...
By Jay S. Kaufman, Los Angeles Review of Books | 09.27.2025
This is the 10th installment in the Legacies of Eugenics series, which features essays by leading thinkers devoted to exploring the history of eugenics and the ways it shapes our present. The series is organized by Osagie K. Obasogie in...
By Julia Black, MIT Technology Review | 10.16.2025
Consider, if you will, the translucent blob in the eye of a microscope: a human blastocyst, the biological specimen that emerges just five days or so after a fateful encounter between egg and sperm. This bundle of cells, about the size of...
By Meagan Parrish, PharmaVoice | 10.10.2025
When CEO Ben Lamm steps into the spotlight, it’s usually to talk about his efforts bringing extinct animals back to life. Once a far-flung idea, Lamm and the company he heads, Colossal Biosciences, have proven they can pull it off...